Yingqian Peng1, Yinan Zhao2, Wenyu Hu3, Yongmei Hu4, Yan He1, Yedi Zhou5. 1. Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. 2. Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110001, China. 3. Department of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110001, China. 4. Center for Disease Control and Prevention of Haidian District, Beijing 100094, China. 5. Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. Electronic address: zhouyedi@csu.edu.cn.
Abstract
OBJECTIVE: Vigabatrin (VGB) is currently served as an effective adjunctive therapy for patients with partial epilepsy worldwide. In this study, meta-analysis was conducted to comprehensively evaluate the changes in peripapillary retinal nerve fiber layer (RNFL) thickness assessed by optical coherence tomography (OCT) in epilepsy patients who were treated by VGB. MATERIAL AND METHODS: Publications on PubMed, Wiley Online Library and the Elsevier Science databases were searched by September 2016. The statistical analysis was performed by RevMan 5.3 software. RESULTS: Four studies were identified, and 202 eyes in VGB-exposed patients (VGB group) as well as 162 eyes in patients who never received VGB treatment (NON-VGB group) were included. The studies demonstrated that the total RNFL thickness is attenuated in VGB treated patients (weighted mean differences in μm, WMD=-15.96, 95% CI: -23.69 to -8.23, P<0.0001). RNFL thickness in 3 quadrants were significantly reduced in VGB group: superior (WMD=-18.15, 95% CI: -23.31 to -12.98, P<0.00001), inferior (WMD=-23.19, 95% CI: -32.23 to -14.15, P<0.00001) and nasal (WMD=-19.29, 95% CI: -35.57 to -3.02, P=0.02). However, the temporal RNFL thickness in these two groups showed no significant difference: temporal (WMD=-2.41, 95% CI: -6.67 to 1.85, P=0.27). CONCLUSION: Based on the meta-analysis, RNFL thickness appears to reduce in epilepsy patients who received VGB treatment, and OCT could be a useful tool to help clinicians assessing its retinal toxicity and guiding its dosage.
OBJECTIVE: Vigabatrin (VGB) is currently served as an effective adjunctive therapy for patients with partial epilepsy worldwide. In this study, meta-analysis was conducted to comprehensively evaluate the changes in peripapillary retinal nerve fiber layer (RNFL) thickness assessed by optical coherence tomography (OCT) in epilepsypatients who were treated by VGB. MATERIAL AND METHODS: Publications on PubMed, Wiley Online Library and the Elsevier Science databases were searched by September 2016. The statistical analysis was performed by RevMan 5.3 software. RESULTS: Four studies were identified, and 202 eyes in VGB-exposed patients (VGB group) as well as 162 eyes in patients who never received VGB treatment (NON-VGB group) were included. The studies demonstrated that the total RNFL thickness is attenuated in VGB treated patients (weighted mean differences in μm, WMD=-15.96, 95% CI: -23.69 to -8.23, P<0.0001). RNFL thickness in 3 quadrants were significantly reduced in VGB group: superior (WMD=-18.15, 95% CI: -23.31 to -12.98, P<0.00001), inferior (WMD=-23.19, 95% CI: -32.23 to -14.15, P<0.00001) and nasal (WMD=-19.29, 95% CI: -35.57 to -3.02, P=0.02). However, the temporal RNFL thickness in these two groups showed no significant difference: temporal (WMD=-2.41, 95% CI: -6.67 to 1.85, P=0.27). CONCLUSION: Based on the meta-analysis, RNFL thickness appears to reduce in epilepsypatients who received VGB treatment, and OCT could be a useful tool to help clinicians assessing its retinal toxicity and guiding its dosage.
Authors: Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson Journal: Neurochem Int Date: 2019-02-26 Impact factor: 3.921
Authors: Dana C Walters; Erwin E W Jansen; Garrett R Ainslie; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Jean-Baptiste Roullet; K M Gibson Journal: Pharmacol Res Perspect Date: 2019-01-07
Authors: Axel Petzold; Philipp Albrecht; Laura Balcer; Erik Bekkers; Alexander U Brandt; Peter A Calabresi; Orla Galvin Deborah; Jennifer S Graves; Ari Green; Pearse A Keane; Jenny A Nij Bijvank; Josemir W Sander; Friedemann Paul; Shiv Saidha; Pablo Villoslada; Siegfried K Wagner; E Ann Yeh Journal: Ann Clin Transl Neurol Date: 2021-05-19 Impact factor: 4.511